Last reviewed · How we verify
Sonacide (GLUTARAL)
Glutaral (Sonacide) is a marketed antiseptic preparation that leverages its mechanism of cross-linking proteins and disrupting cellular membranes to effectively eliminate bacteria and other microorganisms. A key strength of Sonacide is its robust mechanism, which provides broad-spectrum antimicrobial activity. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | GLUTARAL |
|---|---|
| Drug class | glutaral |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Antiseptic preparation
Common side effects
- Pain at injection site
- Headache
- Erythema
- Swelling
- Fever (≥38°C)
Key clinical trials
- Comparative Study of Three Collagen Membranes: 1 Non-cross-linked and 2 Cross-linked (NA)
- Tyrosine Allergoid Paediatric and Adult Study
- Management of Dentin Hypersensitivity in Patients With Periodontitis (NA)
- Gluma Compared With Bonding Agent for Post-operative Sensitivity Following Composite Restorations (PHASE2,PHASE3)
- Evaluation of the Effectiveness of Various Desensitizing Treatment Protocols (NA)
- Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. (PHASE3)
- Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites (PHASE3)
- Comparison of LASER Therapy and Desensitizing Agents in Dentinal Hypersensitivity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sonacide CI brief — competitive landscape report
- Sonacide updates RSS · CI watch RSS